Call Us: (1) 608 441-2729 - Email Us info@flugen.com
Twitter
M2SR: The Vaccine
Influenza
Leadership
Executive Team
Board of Directors
Clinical Advisory Board
Investors
News
Contact
Contact
Careers
News
News and opinions
Watch FluGen President & CEO Paul Radspinner speak at the Jefferies 2021 Virtual Healthcare Conference
June 17, 2021
Katie Radspinner
Influenza
Print Article
https://wsw.com/webcast/jeff174/flu/1704321
Share this Story
Facebook
Twitter
LinkedIn
Reddit
Digg
Delicious
Google++
E-Mail+
Comments are closed.
Prev Post
Next Post
Recent News
M2sr Vaccine Technology: How Flugen Is Introducing New Solutions and Strategies for Influenza and COVID-19 Protection
Dual defense: FluGen’s M2SR vaccine shields against influenza and COVID-19
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults
FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference
(c)2016 FluGen, Inc. All rights reserved.
Twitter
Back to Top
FCOI policy
Comments are closed.